Research fellow: 8+ years experience, Formal training in translational oncology
Experience in therapeutic development and small molecule and biologics drug discovery, cancer cell signaling, metabolism, and immunology, broad technical experience in cell and molecular biology.
Highly collaborative, team player with proven track record of conducting and managing multiple intra and inter-
institutional collaborative projects, preparing standard reports, technical writing, publishing the findings in high caliber journals, and mentoring.
Ph.D.: Biomedical Sciences, Cancer Biology and Cell Biology2014University of Texas Health Science Center at Houston and UT MD Anderson Cancer CenterHouston, Texas, USA
Thesis: Understanding tumor microenvironment influences on miRNA biogenesis
down regulation in cancers
Additional projects on understanding long noncoding
RNA role in cancer metabolism alterations, and hypoxia biology influence on SUMO interactions.
Master of Science: Biotechnology2009University of Texas at San AntonioSan Antonio, Texas, USA
Thesis: Role of TGFBIp induced apoptosis in Diabetes Mellitus and Osteosarcoma
Bachelor of Science: Biotechnology2007Visvesvaraya Technological UniversityBelgaum, India
research experience on plant biology and in vitro clonal propagations, RAPD
based polymorphism studies
Postdoctoral Research Fellow, Dr. Frank Slack Lab07/2015 to CurrentInstitute of RNA Medicine, Beth Israel Deaconess Medical Center, Harvard Medical SchoolBoston, Texas
Managed project on developing of novel small molecule therapeutics for lung
cancer. Developed high throughput assay for small
molecule screen. Independently carried out small molecule screen, involved
liquid handling, automated robotics, and high content imaging. Carried-out
cell-based assays for combination index, Next Gen Sequencing and bioinformatics
analysis to understand biology of novel lead compound, and in vivo testing of therapeutic potential of lead compounds.
Developing noncoding RNA based therapeutics for EGFR and
KRAS mutant lung cancers. Leading and executing the
project on the identification of co-deregulated long noncoding RNAs in EGFR or
KRAS mutant lung cancer patient sample based transcriptome data, functional
characterization using genomic and cell line based tools such as siRNAs, and
currently developing CRISPR techniques.
Postdoctoral Research Fellow, Dr. Anil Sood Lab01/2015 to 07/2015UT MD Anderson Cancer CenterHouston, Texas
Studied the role of SUMO proteins in hypoxia signaling. Used 2 Dimensional Gel Electrophoresis and Mass Spectrometry (MS-MS) to identify potential SUMO binding partners. Investigated effect of SUMO deregulation for cancer survival under hypoxia and in the tumor microenvironment.
Mentored and trained undergraduate and high school students.
Graduate Research Assistant, Dr. Anil Sood Lab08/2009 to 12/2014Graduate School of Biomedical Sciences, UT MD Anderson Cancer Center, UT Health Science CenterHouston, Texas
Project focussed on testing of tumor microenvironment factors influence on the cancer growth and progression, used findings to develop
and test RNA based therapeutic strategies.
Discovered for the first time role of long noncoding RNA called NRCP in regulation of cancer cell metabolism via alteration in
Managed several collaborative projects, and conducted in vivo mouse studies (syngeneic and immune compromised) with
various test therapeutic compounds (small molecule and antibody based) in ovarian, breast and lung cancer.
Used large array of cell based techniques such as transfection, RNA-Seq, development of stable cell lines, and mouse model of ovarian, breast cancers.
Research Assistant, Dr. Richard LeBaron Lab12/2007 to 07/2009University of Texas at San AntonioSan Antonio, Texas
Conducted the project on understanding functions of
protein TGFBIp in osteosarcoma and Diabetes Mellitus.
Identified the protein domain responsible for function of
TGFBIp as apoptosis inducer in the above two diseases.
Used protein and RNA based techniques such as PCR,
cloning, protein production, column based purification, and Western blots
Tutor08/2007 to 12/2007Thomas Rivera Center, University of Texas at San AntonioSan Antonio, Texas
Trained the students on undergraduate level mathematics, biochemistry.
Conducted tutoring classes on need basis.
R Rupaimoole, F J Slack.
MicroRNAs as drugs: New era for therapeutic management of cancer and other
diseases. Nature Reviews in Drug Discovery (Accepted, In press).
R Rupaimoole, F J Slack. A
role for miR- 34 in colon cancer stem cell homeostasis. Stem CellInvestigation
3 42 (2016).
S Y Wu, R Rupaimoole, …
A K Sood. A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic
switch in cancer. Nature Communications DOI:10.1038/ncomms11169 (2016)
B Zand, R A Previs, N M Zacharias, R Rupaimoole, … A K Sood. Role of Increased n-acetylaspartate
Levels in Cancer. Journal of the National Cancer Institute 108 (6) DOI:10.1093/jnci/djv426 (2016)
R Rupaimoole, G A Calin, G
Lopez-Berestein, A K Sood. MiRNA Deregulation in Cancer Cells and the Tumor
Microenvironment. Cancer discovery 6 (3) 235-246 (2016)
R Rupaimoole, C Ivan, D Yang,
S Y Wu, … A K Sood. Hypoxia-upregulated microRNA-630 targets Dicer, leading to
increased tumor progression. Oncogene
R Rupaimoole, J Lee, M
Haemmerle, … A K Sood. Novel noncoding RNA NRCP role in metabolic reprogramming
of cancer cells. Cell Reports 13 2395–2402 (2015)
G Liu, D Yang, R
Rupaimoole, … A K Sood, W Zhang. Augmentation of Response to Chemotherapy
by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers. Journal
of the National Cancer Institute 107 (7): doi: 10.1093/jnci/djv108 (2015)
R Rupaimoole, S Y W, S
Pradeep, … A K Sood. Hypoxia-mediated downregulation of miRNA biogenesis
promotes tumour progression. Nature Communications DOI: 10.1038/ncomms6202
C V Pecot, R Rupaimoole, D Yang, … A K Sood. Tumour angiogenesis regulation by the miR-200
family. Nature Communications. 4 (2013)
R Zamilpa, R
Rupaimoole, C F Phelix, M Somaraki-Cormier, … R G Lebaron. C-terminal
fragment of transforming growth factor beta-induced protein (TGFBIp) is
required for apoptosis in human osteosarcoma cells. Matrix Biology. 28-6: 347-355 (2009)
For Full list please refer to Google Scholar Profile: http://tinyurl.com/j6fuqbc
Molecular Biology: Real Time PCR, Site Directed Mutagenesis, Gene Knockdown
through ShRNA/SiRNA, Northern Blotting, Southern Blotting, ChIP and RIP assay, luciferase system.
Protein techniques: Protein Expression and column based purification from bacterial
and insect cell system, SDS-PAGE, Immunoprecipitation, Western Blotting, Enzyme
Linked Immuno Sorbent Assay (ELISA).
Specialized techniques: Handling and maintenance of human transformed cell lines,
primary cell lines, establishing stable cell lines, blood and immune cells
isolation and flow cytometry analysis, cytokine analysis, robotics and
automated systems, Histological studies including cryo Sectioning, immuno/histology
staining, confocal and fluorescence microscopy, high content imaging.
In vivo: Animal (mouse) handling, orthotropic implantation of
cancer cells for development of ovarian, breast, lung, endometrial, prostate,
liver, spleen, brain tumors, work experience with genetic mouse models.
Programming UNIX and R, NGS data analysis, Rasmol, PDB
Viewer, Ingenuity pathway analysis (IPA), Netwalker.
Aspen Cancer Conference Fellowship, Aspen 2016
President's Research Scholarship, University of Texas Health Science Center and UT MD Anderson Cancer Center, Graduate
School of Biomedical Sciences. 2014
Hawkins discovery fellowship, Graduate School of Biomedical Sciences, UT MD Anderson Cancer Center (3 Yrs). 2010
Member: American Association for Cancer Research, American Association for Advancement of Sciences
day hands-on training in NGS Data Analysis covering NGS-Analysis and UNIX, R
programming. 2016 – TC Chan School of Public Health Bioinformatics core,
Harvard Medical School.
on Oncomine: analysis of data using publicly available data sets. 2014- U.T. MD
Anderson Cancer Center.
on Ingenuity pathway analysis: Practical training on analysis of biological
datasets using Ingenuity tools. 2012- U. T. MD Anderson Cancer Center.